Stockscreener 앱 받기
20.00
5.82%
1.10
전일 마감가:
$18.90
열려 있는:
$18.85
하루 거래량:
183.56K
Relative Volume:
1.65
시가총액:
$168.78M
수익:
순이익/손실:
주가수익비율:
-
EPS:
-
순현금흐름:
1주 성능:
+0.65%
1개월 성능:
-21.57%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$18.16
$20.94
52주 변동 폭
$18.16
$44.28
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Company Profile
Compare YARW vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
YARW
Yarrow Bioscience, Inc. Common Stock
|
20.00 | 168.78M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Yarrow Bioscience, Inc. Common Stock Stock (YARW) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-08-03 | 개시 | BTIG Research | Buy |
| 2025-07-31 | 다운그레이드 | BTIG Research | Buy → Neutral |
| 2024-11-18 | 개시 | BTIG Research | Buy |
| 2021-12-06 | 재개 | H.C. Wainwright | Buy |
Yarrow Bioscience, Inc. Common Stock 주식(YARW)의 최신 뉴스
A passive investor reports ownership of 1 million Yarrow Bioscience (YARW) shares. - Stock Titan
Raymond Debbane Reports 675,000 Shares in Yarrow Bioscience (NASDAQ: YARW) Representing 7.2% Passive Stake - Kalkine Media
New investor group tops 5% in Yarrow Bioscience (YARW) - Stock Titan
Yarrow Bioscience (NASDAQ: YARW) Grants Underwriters 30-Day Option for 865,384 Additional Shares - Kalkine Media
Yarrow Bioscience Raises About $161.8 Million in Public Stock Offering at $26 Per Share - TradingView
Yarrow Bioscience Files Prospectus for 25.78 Million Warrant-Linked Shares Offering (NASDAQ: YARW) - Kalkine Media
Yarrow Bioscience launches public offering of common stock - Investing.com India
Yarrow Bioscience Launches Public Offering of Common Stock - Yahoo Finance
Yarrow Bioscience Announces Pricing of $150 Million Underwritten Public Offering - Business Wire
Yarrow Bioscience prices $150M public offering at $26/share - Investing.com
Yarrow Bioscience Announces Proposed Underwritten Public Offering - Business Wire
YARW SEC FilingsYarrow Bioscience, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update - BioSpace
OrbiMed Advisors Discloses Investment at Yarrow Bioscience with 9.97% Stake - TradingView
Yarrow Bioscience Alters Capital Structure With Warrant Exchange - TipRanks
Yarrow Bioscience, Inc. (YARW) Company Information - Simply Wall Street
Yarrow Bioscience (Nasdaq:YARW)Stock Analysis - Simply Wall Street
Yarrow Bioscience Completes VYNE Merger and Nasdaq Debut - TipRanks
Yarrow Bioscience Completes VYNE Merger and $200 Million Private Financing - citybiz
Yarrow Bioscience Announces Closing of Merger with VYNE Therapeutics and Initiation of Dosing in Phase 2a/2b Trial of YB-101, a Potential First-in-Class Treatment for Graves’ Disease and Thyroid Eye Disease - Yahoo Finance
VYNE Therapeutics Provides Update Regarding Cash Dividend, Reverse Stock Split and Anticipated Timing of Closing of the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split, $17.3M Special Dividend, and Merger with Yarrow Bioscience – Minichart - Minichart
VYNE Sets $17.3M Cash Dividend Before Expected Yarrow Merger - Stock Titan
VYNE Therapeutics Announces 1-for-50 Reverse Stock Split and Provides Update Regarding Special Dividend in Connection with the Proposed Merger with Yarrow Bioscience - Yahoo Finance
VYNE Therapeutics and Yarrow Bioscience Announce Merger to Advance YB-101 for Graves' Disease and Thyroid Eye Disease - Quiver Quantitative
New biotech merger backs antibody targeting Graves’ and thyroid eye disease - Stock Titan
Yarrow Bioscience, Inc. Common Stock (YARW) 재무 분석
Yarrow Bioscience, Inc. Common Stock (YARW)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
1.35%
자본화:
|
볼륨(24시간):